Posters and Presentations :: SCYNEXIS, Inc. (SCYX)

<em>In vitro</em> Evaluation of Combination of Ibrexafungerp and Azoles against <em>Aspergillus</em> spp. Isolated from Lung Transplant Recipients

In vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients

Vidya Jagadeesan, Eileen Driscoll, Binghua Hao, Stephen Barat, Katyna Borroto-Esoda, Tom Chen, David Angulo, Cornelius J Clancy, M. Hong Nguyen
AAAM 2020
February 2020

A Phase 2b, Dose Finding Study Evaluating Oral Ibrexafungerp in Moderate to Severe Acute Vulvovaginal Candidiasis (DOVE)

A Phase 2b, Dose Finding Study Evaluating Oral Ibrexafungerp in Moderate to Severe Acute Vulvovaginal Candidiasis (DOVE)

Nkechi Azie
ISIDOG Congress 2019
November 2019

<em>Aspergillus</em> isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078)

Aspergillus isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078)

Riina Rautemaa-Richardson, Caroline B. Moore, Katie Rawson, Lily Novak-Frazer, David Angulo, Stephen Barat, Malcolm D. Richardson
TIMM 2019
October 2019

Successful Treatment of a Patient with Retroperitoneal Abscess caused by <em>Candida krusei</em> with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

George R. Thompson III, David Angulo
TIMM 2019
October 2019

<em>Candida auris</em> is Highly <em>In Vitro</em> Susceptible to Ibrexafungerp (Formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (Formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary and Maiken Cavling Arendrup
TIMM 2019
October 2019

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against <em>Candida auris: In Vitro, In Vivo</em> and Clinical Case Studies of Candidemia

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

Stephen A. Barat, Katyna Borroto-Esoda, David Angulo
TIMM 2019
October 2019

Activity of Ibrexafungerp (formerly SCY-078) Against <em>Candida auris: In Vitro, In Vivo</em> and Clinical Case Studies of Candidemia

Activity of Ibrexafungerp (formerly SCY-078) Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

Stephen A. Barat, Katyna Borroto-Esoda, Mahmoud Ghannoum, Elizabeth Berkow, Deven Juneja, David Angulo
IDWeek 2019
October 2019

Ibrexafungerp (formerly SCY-078)

Ibrexafungerp (formerly SCY-078)

David Angulo, MD
ASM Microbe 2019
June 2019

Efficacy of Ibrexafungerp (formerly SCY-078) in a Murine Therapeutic Model of <em>Pneumocystis</em> Pneumonia

Efficacy of Ibrexafungerp (formerly SCY-078) in a Murine Therapeutic Model of Pneumocystis Pneumonia

Stephen A. Barat, PhD
ASM Microbe 2019
June 2019

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of <em>Candida auris</em> Cutaneous Infection in a Guinea Pig Model

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of Candida auris Cutaneous Infection in a Guinea Pig Model

M. Ghannoum, L. Long, C. Hager, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019

« Previous
1
2
3
4
5
6
7
8
9
Next »